Heart rate score predicts mortality independent of shocks in ICD and CRT-D patients.

Cardiac resynchronization therapy defibrillator Chronotropic competence Defibrillator shocks Implantable cardioverter defibrillator

Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 28 07 2019
accepted: 12 12 2019
pubmed: 26 12 2019
medline: 19 8 2021
entrez: 26 12 2019
Statut: ppublish

Résumé

Heart Rate Score (HrSc), a novel index found to predict mortality in patients with implantable defibrillator (ICD) and cardiac resynchronization defibrillator (CRT-D) devices, is associated with mortality in ICD and CRT-D recipients when HrSc is ≥ 70%. Implantable defibrillator shocks have also been associated with increased mortality in ICD and CRT-D recipients. The objective of this study was to evaluate the relationships between HrSc, shocks, and mortality in ICD and CRT-D patients. HrSc was calculated from atrial sensed and paced rate histograms collected from the 2006-2011 ALTITUDE remote interrogation database. Shocks were determined in the first year of follow-up. Mortality was assessed over the next 4 years by the Social Security Death Index. Four multivariable models were run: ICD and CRT-D, shock and no shock, with mortality as the outcome and HrS as predictor. Data from 49,358 ICD and 55,953 CRT-D patients were divided into HrSc: ≥ 70%, 30-69%, and < 30%. Shock rates differed between HrSc groups (p < 0.001) for ICD and CRT-D patients. However, the lowest mortality risk HrSc (< 30%) had the highest shock rate. Both highest HrSc (> 70%; p < 0.001) and shocks (p < 0.001) predicted mortality during follow-up. Mortality was unrelated to interactions between HrSc and shocks in ICD patients (p = 0.275) or CRT-D patients (p < 0.079). Comparing HrSc ≥ 70% to HrSc < 30%, HrSc ≥ 70% predicted mortality in CRT-D (HR 1.40; 95% CI 1.29-1.52) and ICD (HR 1.23; 95% CI 1.11-1.36) patients regardless of shocks (P < 0.001 for both). Patients with ICDs or CRT-Ds having the lowest mortality risk HrSc had the highest shock rate. Shocks and HrSc appear to complement each other as predictors of mortality.

Sections du résumé

BACKGROUND BACKGROUND
Heart Rate Score (HrSc), a novel index found to predict mortality in patients with implantable defibrillator (ICD) and cardiac resynchronization defibrillator (CRT-D) devices, is associated with mortality in ICD and CRT-D recipients when HrSc is ≥ 70%. Implantable defibrillator shocks have also been associated with increased mortality in ICD and CRT-D recipients. The objective of this study was to evaluate the relationships between HrSc, shocks, and mortality in ICD and CRT-D patients.
METHODS METHODS
HrSc was calculated from atrial sensed and paced rate histograms collected from the 2006-2011 ALTITUDE remote interrogation database. Shocks were determined in the first year of follow-up. Mortality was assessed over the next 4 years by the Social Security Death Index. Four multivariable models were run: ICD and CRT-D, shock and no shock, with mortality as the outcome and HrS as predictor.
RESULTS RESULTS
Data from 49,358 ICD and 55,953 CRT-D patients were divided into HrSc: ≥ 70%, 30-69%, and < 30%. Shock rates differed between HrSc groups (p < 0.001) for ICD and CRT-D patients. However, the lowest mortality risk HrSc (< 30%) had the highest shock rate. Both highest HrSc (> 70%; p < 0.001) and shocks (p < 0.001) predicted mortality during follow-up. Mortality was unrelated to interactions between HrSc and shocks in ICD patients (p = 0.275) or CRT-D patients (p < 0.079). Comparing HrSc ≥ 70% to HrSc < 30%, HrSc ≥ 70% predicted mortality in CRT-D (HR 1.40; 95% CI 1.29-1.52) and ICD (HR 1.23; 95% CI 1.11-1.36) patients regardless of shocks (P < 0.001 for both).
CONCLUSIONS CONCLUSIONS
Patients with ICDs or CRT-Ds having the lowest mortality risk HrSc had the highest shock rate. Shocks and HrSc appear to complement each other as predictors of mortality.

Identifiants

pubmed: 31875270
doi: 10.1007/s10840-019-00688-8
pii: 10.1007/s10840-019-00688-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-111

Auteurs

Brian Olshansky (B)

Mercy Hospital- North Iowa, Mason City, IA, USA. brian-olshansky@uiowa.edu.
University of Iowa, 200 Hawkins Drive, Room 4426A JCP, Iowa City, IA, 52242, USA. brian-olshansky@uiowa.edu.

Mark Richards (M)

Promedica Physicians Cardiology, Toledo, OH, USA.

Arjun D Sharma (AD)

Boston Scientific, St. Paul, MN, USA.

Paul W Jones (PW)

Boston Scientific, St. Paul, MN, USA.

Nick Wold (N)

Boston Scientific, St. Paul, MN, USA.

David Perschbacher (D)

Boston Scientific, St. Paul, MN, USA.

Bruce L Wilkoff (BL)

Cleveland Clinic, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH